Corporate calendar for Alaunos Therapeutics, Inc. (TCRT): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Stock Splits
| Date | Ratio |
|---|---|
| 2024-07-18 | 1:10 |
| 2024-02-01 | 1:15 |
| 2005-08-24 | 1:40 |
Price
| Price | $1.28 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.00 |
Related companies: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of TCRT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks